Ipsen Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 1/6
Ipsen has been growing earnings at an average annual rate of 3.7%, while the Pharmaceuticals industry saw earnings growing at 3.5% annually. Revenues have been growing at an average rate of 7.5% per year. Ipsen's return on equity is 10.6%, and it has net margins of 11.9%.
Key information
3.66%
Earnings growth rate
3.69%
EPS growth rate
| Pharmaceuticals Industry Growth | 16.27% |
| Revenue growth rate | 7.49% |
| Return on equity | 10.65% |
| Net Margin | 11.91% |
| Next Earnings Update | 12 Feb 2026 |
Recent past performance updates
Recent updates
Ipsen (EPA:IPN) Seems To Use Debt Rather Sparingly
Oct 28
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 41%?
Sep 07Investors Interested In Ipsen S.A.'s (EPA:IPN) Earnings
Jul 13Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.40
May 16Ipsen's (EPA:IPN) Upcoming Dividend Will Be Larger Than Last Year's
Apr 29Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.40
Apr 14
Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025
Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments.Ipsen's (EPA:IPN) Soft Earnings Don't Show The Whole Picture
Feb 21Is Ipsen S.A. (EPA:IPN) Trading At A 44% Discount?
Feb 14Pinning Down Ipsen S.A.'s (EPA:IPN) P/E Is Difficult Right Now
Jan 20Is Ipsen (EPA:IPN) Using Too Much Debt?
Dec 24Revenue & Expenses Breakdown
How Ipsen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 3,760 | 448 | 1,206 | 728 |
| 31 Mar 25 | 3,667 | 402 | 1,190 | 707 |
| 31 Dec 24 | 3,575 | 356 | 1,174 | 687 |
| 30 Jun 24 | 3,435 | 664 | 1,157 | 653 |
| 31 Mar 24 | 3,371 | 641 | 1,146 | 636 |
| 31 Dec 23 | 3,306 | 617 | 1,135 | 619 |
| 30 Jun 23 | 3,282 | 406 | 1,105 | 528 |
| 31 Mar 23 | 3,219 | 500 | 1,072 | 487 |
| 31 Dec 22 | 3,156 | 593 | 1,039 | 445 |
| 30 Sep 22 | 3,053 | 656 | 1,007 | 436 |
| 30 Jun 22 | 2,950 | 719 | 975 | 427 |
| 31 Mar 22 | 2,849 | 675 | 946 | 425 |
| 31 Dec 21 | 2,749 | 631 | 916 | 424 |
| 30 Sep 21 | 2,712 | 626 | 923 | 422 |
| 30 Jun 21 | 2,676 | 622 | 931 | 420 |
| 31 Mar 21 | 2,681 | 585 | 951 | 413 |
| 31 Dec 20 | 2,686 | 548 | 972 | 406 |
| 30 Sep 20 | 2,697 | 249 | 986 | 404 |
| 30 Jun 20 | 2,707 | -50 | 1,000 | 403 |
| 31 Mar 20 | 2,700 | -53 | 1,010 | 396 |
| 31 Dec 19 | 2,693 | -55 | 1,021 | 389 |
| 30 Sep 19 | 2,605 | 176 | 1,003 | 363 |
| 30 Jun 19 | 2,516 | 406 | 986 | 337 |
| 31 Mar 19 | 2,432 | 397 | 970 | 319 |
| 31 Dec 18 | 2,348 | 388 | 954 | 302 |
| 30 Sep 18 | 2,258 | 365 | 931 | 292 |
| 30 Jun 18 | 2,167 | 343 | 909 | 281 |
| 31 Mar 18 | 2,090 | 307 | 883 | 274 |
| 31 Dec 17 | 2,012 | 270 | 858 | 266 |
| 30 Sep 17 | 1,923 | 243 | 821 | 264 |
| 30 Jun 17 | 1,834 | 217 | 785 | 262 |
| 31 Mar 17 | 1,753 | 221 | 752 | 247 |
| 31 Dec 16 | 1,671 | 226 | 719 | 231 |
| 30 Sep 16 | 1,623 | 229 | 703 | 214 |
| 30 Jun 16 | 1,575 | 233 | 687 | 196 |
| 31 Mar 16 | 1,548 | 211 | 676 | 194 |
| 31 Dec 15 | 1,520 | 189 | 666 | 193 |
| 30 Sep 15 | 1,468 | 165 | 651 | 192 |
| 30 Jun 15 | 1,416 | 140 | 636 | 191 |
| 31 Mar 15 | 1,374 | 147 | 606 | 189 |
| 31 Dec 14 | 1,332 | 154 | 577 | 187 |
Quality Earnings: IPN has a large one-off loss of €410.6M impacting its last 12 months of financial results to 30th June, 2025.
Growing Profit Margin: IPN's current net profit margins (11.9%) are lower than last year (19.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IPN has become profitable over the past 5 years, growing earnings by 3.7% per year.
Accelerating Growth: IPN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IPN had negative earnings growth (-32.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-5.8%).
Return on Equity
High ROE: IPN's Return on Equity (10.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 16:08 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ipsen S.A. is covered by 29 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |